1 study found for:    19638622 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Bendamustine

Indicates status has not been verified in more than two years